BioProtect
BioProtect Ltd. develops and commercializes the BioProtect Balloon Spacer, a biodegradable PLCL balloon implant placed transperineally to create prostate–rectum separation during radiation therapy for prostate cancer. It sells the FDA-cleared device to urologists, radiation oncologists, hospitals, and ASCs, and is now part of Olympus following a $270M acquisition.
- Company typePrivate
- Founded2004
- HeadquartersTsur Moshe, Israel
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What BioProtect does
BioProtect Ltd. is an Israel-based medical device company that develops and commercializes the BioProtect Balloon Spacer (BioProtect Balloon Implant System), a pre-formed, biodegradable balloon implant made of Poly(L-lactide-co-ε-caprolactone) (PLCL) that is placed via the transperineal route under transrectal ultrasound guidance and inflated in situ with saline to create 10–18 mm of uniform prostate–rectum separation during radiation therapy for prostate cancer. The device is fully bioresorbed by the patient over the course of treatment, is visible under TRUS, CT, and MRI, and is the only FDA-cleared (510(k) K222972, August 2023) non-gel balloon spacer in the rectal-protection category, supported by a pivotal Phase III RCT of 222 patients and 26+ peer-reviewed publications. BioProtect's clinical positioning emphasizes consistent base-to-apex spacing, SBRT-grade rectal dose reduction (>84% rV70 reduction), and four-year sustained bowel, urinary, and sexual quality-of-life preservation as differentiated performance versus gel-based hydrogel spacers (SpaceOAR, Barrigel).
The company sells the device as a single-use implantable medical device to urologists, radiation oncologists, physicists, dosimetrists, hospitals, and ambulatory surgical centers, with procedure-based Medicare reimbursement of approximately $5,114 in the HOPD setting and $4,248 in the ASC setting (CPT 55874, HCPCS C1889). The go-to-market is built on direct field sales, a hands-on physician and resident training program, a multi-episode masterclass series, and a deep presence at ASTRO, AUA, ABS, and regional urological society meetings. Since the 2023 US commercial launch, more than 11,000 procedures have been performed worldwide and BioProtect generated approximately $14.5 million in 2025 revenue. In May 2026, Olympus Corporation signed a definitive agreement to acquire BioProtect for $270 million (expected to close end of Q2 2026), making the company part of Olympus's global urology and oncology commercial channel.
BioProtect firmographics
Firmographics- Name
- BioProtect
- Legal name
- BioProtect Ltd.
- Website
- https://bioprotect.com
- Company type
- Private
- Founded year
- 2004
- Operating status
- Acquired
- Headcount range
- 101–250 employees
- Short description
- BioProtect Ltd. develops and commercializes the BioProtect Balloon Spacer, a biodegradable PLCL balloon implant placed transperineally to create prostate–rectum separation during radiation therapy for prostate cancer. It sells the FDA-cleared device to urologists, radiation oncologists, hospitals, and ASCs, and is now part of Olympus following a $270M acquisition.
- Ownership category
- akta.pro rank
BioProtect industry classification
Industry- Product category
- Radiation Oncology Medical Devices
- NAICS
- Medical Equipment and Supplies Manufacturing (3391), Irradiation Apparatus Manufacturing (334517), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), X-Ray Apparatus & Tubes & Related Irradiation Apparatus (3844)
- akta.pro primary industry
- Radiation Oncology (HLAKAFAC)
- akta.pro secondary industry
- 3D-Printed & Patient-Specific Implants (Custom Ortho/Spine/Cranial) (HLAHAEAJ)
Keywords
Where BioProtect is headquartered
LocationHeadquarters
- HQ city
- Tsur Moshe
- HQ country
- Israel
- HQ region
- Middle East
Markets served
BioProtect business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Marketing or Sales, Technology or R&D, Supply Chain, Operations, Infrastructure
Revenue model
- BioProtect Balloon Implant Device Sales: Revenue generated from sale of the FDA-cleared BioProtect Balloon Implant System to hospitals, ambulatory surgical centers, and physician offices for use during prostate cancer radiation therapy. Approximately $14.5 million in revenue in 2025; over 11,000 procedures performed since 2023 commercial launch. Device is billed via CPT 55874 with HCPCS C1889 for the biodegradable spacer material.
- Procedure Reimbursement-Driven Sales: Hospital Outpatient Department payment of approximately $5,114 per procedure and ASC payment of approximately $4,248 for CPT 55874 transperineal placement of biodegradable material, supporting the per-unit economics that drive device adoption and recurring hospital purchasing.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | CPT 55874 - Transperineal placement of biodegradable material, periprostatic (Hospital Outpatient / ASC) |
| Unit Pricing | Pay-as-you-go | CPT 55876 - Placement of fiducial marker into prostate for radiation therapy guidance |
| Unit Pricing | Pay-as-you-go | CPT 77387 (formerly G6002) - Image guidance utilizing stereoscopic X-ray guidance |
Go-to-market motion3 records
Distribution channels2 records
Marketing channels13 records
BioProtect product offering
Product offeringCore offering
BioProtect develops, manufactures, and sells the BioProtect Balloon Spacer (BioProtect Balloon Implant™ System), an FDA 510(k)-cleared, biodegradable balloon implant placed via the transperineal route under transrectal ultrasound guidance and inflated with saline to create 10–18 mm of prostate–rectum separation during radiation therapy for prostate cancer. The device is fully bioabsorbed by the patient after treatment and is sold to hospitals, ambulatory surgical centers, and urology/radiation oncology practices, supported by physician training, clinical evidence, and reimbursement services.
Product overview
BioProtect offers a single unified core product, the BioProtect Balloon Spacer (BioProtect Balloon Implant™ System), a biodegradable, pre-formed balloon implant placed via a transperineal approach and inflated with saline to create 10–18 mm of prostate–rectum separation during prostate cancer radiation therapy. The core product is delivered alongside an integrated ecosystem of clinical and educational services that support adoption and use, including the BioProtect Balloon Spacer Procedure (workflow and placement guidance), a Physician Training Program, a Resident Training Program, BioProtect Masterclasses (live and on-demand expert education), the BioProtect Resource Center (imaging library and downloadable materials), the BioProtect Clinical Evidence Program (pivotal phase III trial and 20+ supporting studies), and BioProtect Reimbursement Support (Medicare billing codes and payment rates). Together, the device plus these training, evidence, and reimbursement services form a single platform for integrating balloon spacing into prostate cancer radiotherapy practice; BioProtect became part of Olympus in 2026.
Differentiator
Problem solved
Functional benefit
Brands
- BioProtect Balloon Spacer: The company's flagship product brand: a biodegradable balloon implant system that creates spacing between the prostate and rectum during prostate cancer radiation therapy to protect healthy tissues.
- BioProtect Balloon Implant System
Products and services
- BioProtect Balloon Spacer (BioProtect Balloon Implant™ System) The BioProtect Balloon Spacer is a pre-formed, biodegradable (Poly(L-lactide-co-ε-caprolactone), PLCL) balloon implant placed via a transperineal approach under TRUS guidance and inflated in situ with standard 0.9% saline to create 10–18 mm of uniform prostate–rectum separation during prostate cancer radiation therapy, reducing rectal dose and preserving bowel, urinary, and sexual quality of life; it is fully resorbed by the body after treatment. It is sold to hospitals, ambulatory surgical centers, and urology/radiation oncology practices for use under CPT 55874 with HCPCS C1889.
Companies that use BioProtect
Customer profileNamed customers11 records
Segments5 records
Ideal customer profiles3 records
BioProtect technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
BioProtect partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered flagship, core and minor.
- Olympus CorporationflagshipOlympus Corporation signed a definitive agreement to acquire BioProtect Ltd. for $270 million in May 2026, with completion expected by the end of Q2 2026. The acquisition expands Olympus's urology and oncology portfolio and aligns with its strategic pillar of Innovation-driven Growth; BioProtect becomes part of Olympus's global commercial channel for prostate cancer care technologies.
- American Brachytherapy Society (ABS)coreBioProtect is an industry partner at the American Brachytherapy Society Annual Meeting 2026, hosting booth #110 and a Thursday, June 18, 2026 breakfast symposium titled 'Beyond Placement: Rethinking Rectal Spacing in Modern Brachytherapy' featuring Drs. Chase Hansen, Sagar A. Patel, Albert J. Chang, and Tomer Charas.
- American Urological Association (AUA)coreBioProtect holds major presence at the American Urological Association Annual Meeting 2026 in Washington D.C. (booth #3815, product theater presentation, VIP educational dinner event titled 'Next-Level Spacing for the Modern Urology Practice', and The Apex Series of in-depth physician presentations).
- Prostate Health PodcastminorBioProtect makes sponsored/featured appearances on The Prostate Health Podcast hosted by Dr. Garrett D. Pohlman, with panelists including Dr. Jeffrey Wolters and Dr. Coyt Rountree discussing innovations in prostate cancer care and benefits of BioProtect in urological practice.
- OncoDailyminorBioProtect developed the article 'Spacing for Prostate Radiotherapy: Definitions, Mechanisms, Advancements, and Evolving Strategies' in collaboration with OncoDaily, with original publication on OncoDaily.com.
Scale indicators12 records
Recent moves6 records
Expansion highlights6 records
BioProtect competitors and assessment
Company assessmentDirect peers
- Boston Scientific: Owns SpaceOAR, the leading PEG-hydrogel rectal spacer for prostate cancer radiation therapy acquired via Augmenix. Directly comparable as the dominant gel-based competing spacer with overlapping customers (urologists and radiation oncologists) and the same clinical indication.
- Palette Life Sciences: Markets Barrigel, a hyaluronic acid-based rectal spacer for prostate radiation therapy. Direct competitor in the same clinical indication, cited in BioProtect's own comparative evidence (BioProtect vs. Barrigel in proton therapy).
Broad incumbents
- Elekta: Global leader in radiation oncology hardware and software (linear accelerators, brachytherapy afterloaders, treatment planning). Comparable as the broader ecosystem into which BioProtect's spacer integrates; not a direct spacer competitor but a strategic channel and adjacent incumbent.
- Varian Medical Systems (Siemens Healthineers): Radiation oncology systems and software provider (now part of Siemens Healthineers). Comparable as the dominant linear-accelerator and treatment-planning vendor whose installed base defines where BioProtect spacers are used, and a potential integrator of spacer functionality into its planning ecosystem.
- Eckert & Ziegler: Provider of brachytherapy seeds and radiation oncology products used in prostate cancer treatment. Comparable as an adjacent incumbent in the prostate radiation therapy workflow that serves the same radiation oncologist customers.
Emerging players
- Theragenics: Brachytherapy seed and prostate cancer treatment device company. Comparable as a niche prostate-radiation supplier addressing overlapping radiation oncology buyers, though focused on seeds rather than spacers.
- Profound Medical: Developer of TULSA-PRO, an MRI-guided transurethral ultrasound ablation system for prostate tissue. Comparable as an emerging, technology-focused prostate cancer therapy company targeting overlapping urology customers seeking tissue-sparing approaches.
- EDAP TMS: Markets Focal One, a robotic HIFU system for prostate tissue ablation. Comparable as a focal-therapy prostate device company selling to the same urologist customer base that places spacers pre-radiation.
- IsoRay Medical: Producer of Cesium-131 brachytherapy seeds for prostate cancer. Comparable as a small-cap prostate radiation therapy device vendor addressing the same radiation oncology segment.
Others
- AngioDynamics: Interventional oncology and vascular device company. Adjacent rather than directly competing — comparable as a mid-sized medtech with overlapping oncology distribution channels and physician relationships.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat6 records
Key risks6 records
Key highlights6 records
Customer concentration
BioProtect social profiles
Digital presenceBioProtect compliance and trust
Trust signalCompliance3 records
BioProtect financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioProtect leadership team
Management profileNumber of profiles
Profiles10 records
BioProtect funding detail
Funding detailFunding overview
Funding rounds9 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioProtect M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioProtect
What does BioProtect do?
BioProtect develops, manufactures, and sells the BioProtect Balloon Spacer (BioProtect Balloon Implant™ System), an FDA 510(k)-cleared, biodegradable balloon implant placed via the transperineal route under transrectal ultrasound guidance and inflated with saline to create 10–18 mm of prostate–rectum separation during radiation therapy for prostate cancer. The device is fully bioabsorbed by the patient after treatment and is sold to hospitals, ambulatory surgical centers, and urology/radiation oncology practices, supported by physician training, clinical evidence, and reimbursement services.
Is BioProtect a public or private company?
BioProtect is a private company. It is classified as corporate owned and is currently acquired.
When was BioProtect founded?
BioProtect was founded in 2004. It employs 101 to 250 people.
Where is BioProtect based?
BioProtect is headquartered in Tsur Moshe, Israel, in the Middle East region.
How does BioProtect make money?
Two revenue lines are on record. BioProtect Balloon Implant Device Sales are the primary driver. The others are procedure Reimbursement-Driven Sales.
Who are BioProtect's main competitors?
Direct peers on record are Boston Scientific and Palette Life Sciences. Broad incumbents are Elekta, Varian Medical Systems (Siemens Healthineers) and Eckert & Ziegler. Emerging players are Theragenics, Profound Medical, EDAP TMS and IsoRay Medical. AngioDynamics is listed as an others.
Does BioProtect have an API?
No public API is recorded for BioProtect.
What industry is BioProtect in?
BioProtect's product category is Radiation Oncology Medical Devices. Its primary akta.pro industry code is HLAKAFAC, Radiation Oncology, with a secondary code of HLAHAEAJ, 3D-Printed & Patient-Specific Implants (Custom Ortho/Spine/Cranial). Its NAICS code is 3391 and its SIC code is 3841.